Long-acting HIV shot study aims to make prevention fairer for all
NCT ID NCT07620730
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a long-acting injectable HIV prevention drug (cabotegravir) can be delivered fairly and effectively in NHS sexual health clinics. Researchers will follow 200 people taking the drug for 12 months, along with 20 healthcare professionals, to see how well it works in real-world settings and whether it reaches groups often underserved by current prevention options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
long-acting cabotegravir (LA CAB)
What this could lead to
If successful, this could show that long-acting injectable PrEP is a practical and equitable option for HIV prevention in the NHS, especially for underserved groups.
What could go wrong
This is an implementation study, not a test of the drug itself. It may reveal barriers that limit uptake or persistence, and results may not apply outside the UK.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREP are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••